DalsnaFinance › IPOs › Aktis Oncology Inc › IPO
Aktis Oncology, Inc. completed its initial public offering on NASDAQ on January 9, 2026, pricing at $18.00 a share.
| Ticker | AKTS |
|---|---|
| Exchange | NASDAQ |
| Status | Completed |
| Listing date | January 9, 2026 |
| Offering price | $18.00 |
| Shares offered | 17,650,000 |
| Total raised | $318M |
Aktis Oncology, Inc. sold 17,650,000 shares at $18.00 each on NASDAQ. Multiplied out, that is $317.7 million in gross proceeds, the figure before underwriting discounts and offering expenses, and it agrees with the $318 million total recorded for the deal.
Measured by money raised, Aktis Oncology, Inc. was the 83rd largest of 473 completed IPOs with a recorded deal size that this site tracks since October 5, 2024. The median deal in the same window raised $200 million, so this one was about 1.6 times the typical size.
Among the 342 listings on NASDAQ alone, it is the 42nd largest.
January 2026 saw 33 completed IPOs in the site's data; by amount raised, Aktis Oncology, Inc. was the 4th largest of the 33 deals with a recorded size.
Its $18.00 offer price was tied for the 82nd highest (level with 12 other listings) of the 479 listings in the window with a recorded price. A share price on its own says nothing about a company's value; it depends on how many shares exist.
Aktis Oncology, Inc. — quote, profile and latest news →
Source: SEC EDGAR filings for Aktis Oncology, Inc.. This page is general information, not investment advice.